AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (0.62%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.76 -0.02 (-2.48%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ALVR 0.78 0.00(0.62%)
Will ALVR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALVR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALVR
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
ALVR: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Rising P/E to Bet on for Solid Gains
5 Top-Ranked Stocks With Rising P/E Worth Investing In
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Other News for ALVR
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024
AlloVir Ends Lease Agreement with AMAG Pharmaceuticals
AlloVir Approves Executive Bonuses for Potential 2024 Buyout